DNAtrix has announced that the first patients have been treated in a multicentre Phase 2 trial investigating its oncolytic adenovirus, DNX-2401, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients suffering with recurrent glioblastoma.

The CAPTIVE study is analysing the potential impact of DNX-2401 and KEYTRUDA in patients with recurrent glioblastoma, a disease for which there is neither a cure nor enough treatment.

Leading medical centres in the US and Canada are taking part in the study.

DNX-2401 is a conditionally replicative oncolytic adenovirus targeting and killing cancer cells, whilst leaving normal cells intact.

Several clinical studies have indicated that DNX-2401 has a favourable safety profile, strong tumour-killing potential and can trigger an anti-tumour immune response.

KEYTRUDA is a humanised monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This activity boosts the T-cell response and leads to effective tumour destruction.

"Based on remarkable preclinical data, we anticipate that the addition of KEYTRUDA to DNX-2401 therapy will provide even more benefit to patients with recurrent disease."

KEYTRUDA is currently approved in the US for advanced melanoma, metastatic non-small-cell lung cancer (NSCLC), and advanced head and neck squamous cell cancer (HNSCC).

DNAtrix CEO Frank Tufaro said: “Glioblastoma is a difficult disease to treat with conventional therapies.

“Based on remarkable preclinical data, we anticipate that the addition of KEYTRUDA to DNX-2401 therapy will provide even more benefit to patients with recurrent disease.”

DNAtrix is a clinical stage biotechnology company developing virus-driven immunotherapies for cancer.


Image: MRI suggesting glioblastoma in a 15-year-old boy. Photo: courtesy of Christaras A / Wikipedia